Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOTIC-018: Nivolumab with Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
jRCT1091220425Phase 1Completed
- Sponsor
- Kosei Hasegawa
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in Cervical Cancer (CC) (3 cohorts), sponsored by Kosei Hasegawa. Primary endpoints: Rates of acute phase adverse events grade >3 in cohort A and Rates of acute phase adverse events grade >3 in cohort B. Started May 2019; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT1091220425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220425.